Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367592 | 1.00 | CYP2D6 (0.58) | CYP2D6CYP2C19SLC7A5ANPEPDNPEP | |
| SCHEMBL20956354 | 1.00 | CYP2D6 (0.58) | CYP2D6CYP2C19SLC7A5ANPEPDNPEP | |
| SCHEMBL856065 | 0.80 | — | — | |
| SCHEMBL4528459 | 0.80 | — | — | |
| SCHEMBL842714 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL25286260 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL899324 | 0.78 | — | — | |
| SCHEMBL1978558 | 0.76 | CYP2D6 (0.47) | CYP2D6CYP2C19ANPEPDNPEP | |
| SCHEMBL28716386 | 0.75 | CYP2D6 (0.64) | CYP2D6CYP2C19SLC7A5ECE1MAPT | |
| SCHEMBL6728230 | 0.75 | CYP2D6 (0.64) | CYP2D6CYP2C19SLC7A5ECE1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108434149-A | For the regulated treatments of HSPC of Rb positive abnormal cell proliferations | G1治疗公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-108283644-A | To the instantaneous protection of normal cell during chemotherapy | G1治疗公司 | 2018-07-17 | — | — | CN | disclosed |
| CN-105407889-B | HSPC-sparing therapy for Rb-positive abnormal cell proliferation | G1治疗公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-105473140-B | Transient protection of normal cells during chemotherapy | G1治疗公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-106008533-B | CDK inhibitor | G1治疗公司 | 2018-01-23 | — | — | CN | disclosed |
| CN-107417691-A | Efficient anti-superfluous raw agent and anti-proliferative agent | G1治疗公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-106967074-A | CDK inhibitor | G1治疗公司 | 2017-07-21 | — | — | CN | disclosed |
| CN-103936745-B | Cdk inhibitors | G1治疗公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-106008533-A | Cdk inhibitors | G1治疗公司 | 2016-10-12 | — | — | CN | disclosed |
| EP-2336122-B1 | 1-PYRIMIDINYL- OR 1-PYRIDINYL-2-AMINO BENZIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES FOR THE TREATMENT OF CANCER | VERTEX PHARMA (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8076343-B2 | Benzimidazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-13 | — | — | US | disclosed |
| EP-1937667-B1 | BENZIMIDAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-1937667-A2 | BENZIMIDAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-03 | — | — | US | disclosed |
| WO-2007015923-A2 | BENZIMIDAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099920-A1 | Benzimidazoles useful as inhibitors of protein kinases | PDK1, AURKC, PIM3 | CYP2D6 2981/4885CYP2C19 2044/4885SLC7A5 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.